← All trials
NCT03466827
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2017
- Primary completion
- Jul 1, 2020
- Completion date
- Jul 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 25
- Arms / groups
- — / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- Institut Gustave RoussyCollaborator
- Karyopharm Therapeutics IncCollaborator
- University of LyonCollaborator
- University of CopenhagenSponsor investigator
- University of CopenhagenStudy director
- Curie InstituteCollaborator
- GSO Global Clinical Research BVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.